CD19 plays an important role in the B-cell receptor pathway and is expressed at an earlier stage than CD20 in both normal and malignant B cells so it is another desirable target for treating B-cell lymphoma. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.